Physician profile
Thomas M Strobel
NPI 1164050084
$1,445.60
in general payments reported to CMS, 2019-2025
19 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.75 · 2022: $229 · 2023: $121 · 2024: $727 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $240.63 | 2024 | |
| Medtronic, INC. | $160.26 | 2025 | Percept PC Brainsense |
| Novartis Pharmaceuticals Corporation | $137.61 | 2024 | |
| Acorda Therapeutics, INC | $122.00 | 2021-2023 | Inbrija |
| Alexion Pharmaceuticals, INC. | $116.85 | 2024 | Ultomiris, Soliris |
| Jazz Pharmaceuticals INC. | $92.10 | 2022-2023 | |
| Ucb, INC. | $85.50 | 2025 | Fintepla |
| Tanabe Pharma America, INC. | $75.69 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $74.83 | 2022-2024 | Nuplazid |
| Eisai INC. | $74.73 | 2024 | |
| Abbvie INC. | $70.88 | 2022-2023 | |
| Argenx US, INC. | $41.79 | 2024 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $28.86 | 2024 | Rexulti |
| Neurelis, INC. | $28.41 | 2025 | Valtoco |
| Mdd US Operations, LLC | $24.39 | 2024 | Apokyn |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $19.97 | 2024 | |
| Biogen, INC. | $19.32 | 2024 | Skyclarys |
| Catalyst Pharmaceuticals, INC. | $16.60 | 2023 | Fycompa |
| Biohaven Pharmaceuticals, INC. | $15.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Strobel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.